DadFinStart your free week
DadFin › Stocks › Healthcare › ZTS

Zoetis Inc. (ZTS) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$74.81 ▲ +2.37% today

61.2
Dad Score, out of 100
middling

Zoetis Inc. (ZTS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 61.2 out of 100 on the Dad Score, a middling reading that places the business ahead of 61% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #333 of 974. Its strongest axes are valuation, quality and liquidity; its weakest are growth and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Strong
Growth
Below average
Price action
Weak
Risk
Average
Conviction
Average
Liquidity
Strong
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)11.4×
P/E (forward)10.6×
Dividend yield2.98%
Return on capital27.1%
Operating margin40.7%
Revenue growth (YoY)+2.3%
FCF yield6.4%
Net debt / EBITDA1.86×
Piotroski F-Score6 / 9
52-week change-51.1%
Market cap$28.8B
Next earningsNov 5, 2026

What subscribers see on ZTS

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B
RDYDr. Reddy's Laboratories Limited28.5weak$10.2B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.